Gastroenterologie up2date, Table of Contents Gastroenterologie up2date 2025; 21(01): 6-8DOI: 10.1055/a-2461-0209 Wichtige Studien im Fokus Kommentar zu: Cabozantinib bei vorbehandelten, progredienten neuroendokrinen Tumoren Anja Rinke Recommend Article Abstract Buy Article All articles of this category Comment on: Cabozantinib bei vorbehandelten, progredienten neuroendokrinen TumorenGastroenterologie up2date 2025; 21(01): 6-6DOI: 10.1055/a-2504-4908 Full Text References Literatur 1 Raymond E, Dahan L, Raoul JL. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513 2 Chan J, Faris J, Murphy J. et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). J Clin Oncol 2017; 35(4 suppl) 3 Chan JA, Geyer S, Zemla T. et al. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med 2025; 392: 653-665 4 Yao JC, Fazio N, Singh S. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387: 968-977
